In part 1 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the Boehringer Ingelheim relationship with Eli Lilly and the cardiovascular effects of certain diabetes medications.
Read More »Daily Archives: Mar 16, 2018
Thomas Seck Part 2, New Data on Empagliflozin
In part 2 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the medications presented at the conference and the benefits of these treatments.
Read More »Thomas Seck Part 3, Empagliflozin Precautions and Side Effects
In part 3 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about patient responses to the latest medications and side effects.
Read More »Thomas Seck Part 4, Empagliflozin Effects on Cardiovascular Disease
In part 4 of this Exclusive Interview, Dr. Thomas Seck shares his thought about Empagliflozin as it relates to diabetes professionals in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.
Read More »Thomas Seck Part 5, The Cost of Empagliflozin for Patients
In part 5 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about costs and benefits of Empagliflozin for patients as well as insurance companies.
Read More »Thomas Seck Part 6, Cardiovascular Disease and Type 2 Diabetes
In part 6 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the impact of heart disease on the patient with diabetes.
Read More »Thomas Seck Part 7, The Future For Boehringer Ingelheim
In part 7 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about what's coming up next for Boehringer Ingelheim and knowing the right patient to treat with the newest drugs.
Read More »Thomas Seck Part 8, Empagliflozin Effects On Prediabetes
In part 8 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about plans to study the effects of Empagliflozin in patients with prediabetes.
Read More »Thomas Seck Part 9, Final Thoughts
In part 9, the conclusion of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the importance of adding diet and exercise to a treatment regimen.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.